23-HN-38-BG(BGB-HNSCC-201):A Phase 2, Randomized, Open-label, multi-arm Study of Tislelizumab in Combination with Investigational Agents as First Line Treatment in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma